AC
ZVRA icon

Armistice Capital’s Zevra Therapeutics ZVRA Stock Holding History

Armistice Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-268,000
Closed -$1.76M – 420
2023
Q4 		$1.76M Buy
+268,000
New +$1.25M 0.02% 159

Other funds holding ZVRA

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Armistice Capital's ZVRA Position: Q1 2024 in Review

Armistice Capital sold out of Zevra Therapeutics (ZVRA) in Q1 2024, closing a stake of 268,000 shares — an estimated $1.76M sold.

Armistice Capital first reported a position in ZVRA in Q4 2023 and held it in 1 quarter. The position peaked at $1.76M in Q4 2023. 89 funds tracked by Wall St. Rank hold ZVRA as of Q1 2024.

  • Armistice Capital reported no remaining Zevra Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Armistice Capital sold 268,000 Zevra Therapeutics shares in Q1 2024, an estimated $1.76M.
  • Armistice Capital first reported a position in Zevra Therapeutics in Q4 2023 and held it in 1 quarter.
  • Armistice Capital's Zevra Therapeutics position peaked at $1.76M in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.